SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (17060)3/10/1998 11:27:00 AM
From: Henry Niman  Respond to of 32384
 
Bernie, I thought that I posted something last night, but can't find it. The current press release mentions Europe and I still think that it's the SRGN compound that requires IV injection. I suspect that administration requires extensive training, so the launch costs may be higher than initially realized (to train hospital personnel in the US and Europe) and short term (by 1999) profitability may be a question mark, even if the product is approved.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News